Compare PFAI & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFAI | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 34.6M |
| IPO Year | 2024 | 2020 |
| Metric | PFAI | ALGS |
|---|---|---|
| Price | $4.93 | $5.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $52.38 |
| AVG Volume (30 Days) | ★ 3.1M | 37.9K |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $1,562.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.00 | $3.98 |
| 52 Week High | $7.02 | $13.69 |
| Indicator | PFAI | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 43.73 |
| Support Level | $3.56 | $4.97 |
| Resistance Level | $7.02 | $6.91 |
| Average True Range (ATR) | 0.89 | 0.32 |
| MACD | 0.22 | 0.01 |
| Stochastic Oscillator | 56.98 | 33.33 |
Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.